Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGB-16673 combination study in relapsed or refractory B-cell malignancies
2024-516234-35-00Phase 2Authorised
- Sponsor
- BeOne Medicines
- Start
- Oct 2025
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Countries
- 8
01
Overview
Phase 2, open-label trial of catadegbrutinib in B-cell malignancy (4 arms), sponsored by BeOne Medicines. Primary endpoints: Number of patients with dose-limiting toxicities, Number of patients with treatment-emergent adverse events and 2 more. Planned start Oct 2025; status: authorised.
02
Drugs
catadegbrutinib
03
Conditions
B-cell malignancy
Beyond the preview
Go deeper on 2024-516234-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516234-35-00.